Novo Nordisk

Patient groups still think ViiV is tops, with Novo and AbbVie close behind
Fierce Pharma Marketing
Wed, 02/11/15 - 09:47 am
ViiV
Novo Nordisk
AbbVie
patients
Merck and Novo join an open-source R&D club with Amgen, Sanofi and Ono
Fierce Biotech
Tue, 02/10/15 - 10:40 am
R&D
Merck
Novo Nordisk
Amgen
Sanofi
Ono Pharmaceutical
Sanofi undertakes major sales reorg of US diabetes business
BioPharma Dive
Tue, 02/10/15 - 10:39 am
Sanofi
Novo Nordisk
diabetes
reorganization
Big Pharma Faces Some Big Patent Losses, but Pipelines are Improving
WSJ Pharmalot
Tue, 02/10/15 - 08:41 am
patents
Big Pharma
Abilify
Amgen
AstraZeneca
Biogen Idec
Bristol-Myers Squibb
Crestor
Eli Lilly
Gilead Sciences
GSK
Harvoni
Hospira
Merck
Novo Nordisk
Pfizer
Sovaldi
Tecfidera
Novo Nordisk joins pharma's IPO clique with plans for tech subsidiary spinoff
Fierce Pharma
Mon, 02/9/15 - 10:35 am
Novo Nordisk
IPOs
spinoffs
NNIT
Forget Pfizer! This Big Pharmaceutical Stock is Better
Motley Fool
Sun, 02/8/15 - 10:03 am
Pfizer
Novo Nordisk
Moody's: Patent-cliff challenges will continue to dog big pharma
BioPharma Dive
Wed, 02/4/15 - 01:43 pm
patents
patent cliff
Big Pharma
Pfizer
Eli Lilly
Merck
Amgen
Novo Nordisk
AstraZeneca
Bristol-Myers Squibb
Victoza powers Novo's strong year; CEO projects growth for 2015
Fierce Pharma
Fri, 01/30/15 - 11:15 am
Novo Nordisk
earnings
Pharma CEOs
Victoza
Lars Sorenson
Novo Nordisk puts 500 Saxenda reps on U.S. streets, aiming for $1B in weight-loss sales
Fierce Pharma
Tue, 01/27/15 - 08:41 am
Novo Nordisk
Saxenda
drug reps
Novo Nordisk stock rises on $2 billion buyback
Marketwatch
Mon, 01/26/15 - 08:10 am
Novo Nordisk
stock buybacks
Novo Nordisk Plans to Move Forward With Investments in Russia
Bloomberg
Fri, 01/23/15 - 08:32 am
Novo Nordisk
Russia
FirstWord Lists – The drugs that will shape 2015
First Word Pharma
Mon, 01/19/15 - 04:14 pm
Harvoni
Viekira Pak
Gilead Sciences
AbbVie
alirocumab
evolocumab
Amgen
Regeneron
Sanofi
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Novartis
CTL019
Zarxio
Pfizer
palbociclib
Saxenda
Trulicity
Afrezza
MannKind
Eli Lilly
Novo Nordisk
LCZ696
Toujeo
Breo Ellipta
GED-0301
Celgene
BiogenIdec
5 Obesity Stocks Investors Are Watching
Yahoo/Benzinga
Thu, 01/15/15 - 08:53 am
obesity
Orexigen
Contrave
Arena Pharmaceuticals
Belviq
APD334
Vivus
Qsymia
EnteroMedics
devices
Maestro System
Novo Nordisk
Saxenda
Next-Generation Diabetes Drug Offers Great Growth Potential
Motley Fool
Sat, 01/10/15 - 01:11 pm
diabetes
Novo Nordisk
Perle Biosciences
PRL001
PRL002
JNJ
AstraZeneca
Bristol-Myers Squibb
Grading Pharma In 2014: 17 Drug Companies Ranked
Forbes
Sun, 01/4/15 - 10:24 pm
Actavis
Celgene
Amgen
AbbVie
Gilead Sciences
Eli Lilly
Novartis
AstraZeneca
Merck
JNJ
Biogen Idec
Novo Nordisk
Roche
Bristol-Myers Squibb
Pfizer
GSK
Sanofi
Novo Nordisk A/S - Status regarding Novo Nordisk's holding of its own shares
Yahoo/Globe NewsWire
Sat, 01/3/15 - 10:58 am
Novo Nordisk
Novo Nordisk to promote drug to treat obesity in United States
Yahoo/Reuters
Mon, 12/29/14 - 11:13 am
Novo Nordisk
obesity
Saxenda
Novo Nordisk CEO Speaks Of Short-Term Challenges That Could Limit Growth
Bidness Etc.
Mon, 12/29/14 - 11:03 am
Novo Nordisk
Pharma CEOs
insulin
Tresiba
Lars Sorenson
Novo Nordisk CEO sees short-term challenges to growth - paper
Yahoo/Reuters
Sat, 12/27/14 - 10:33 am
Novo Nordisk
4 Potential Blockbuster Drugs The FDA Just Approved
Investors.com
Fri, 12/26/14 - 10:11 pm
Bristol-Myers Squibb
Opdivo
Merck
Cubist Pharmaceuticals
Zerbaxa
AstraZeneca
Lynparza
Novo Nordisk
Saxenda

Pages